Clinical research reveals GLP-1 receptor agonists provide significant health benefits beyond weight loss, including lowering biological aging markers and extending lifespan in animal models. Studies demonstrate semaglutide and tirzepatide protect heart, kidney, and liver function while reducing knee osteoarthritis pain. Recent data from U.S. health records and upcoming trials show these medications lower psychiatric hospitalizations by 24% for schizophrenia patients and reduce emergency room visits.
GLP-1 anti-aging effects
- ▪A University of California, Berkeley study in Nature showed 20-month-old mice treated with semaglutide achieved an average lifespan of 834 days compared to 742 days for placebo-treated mice.
- ▪A Novo Nordisk preprint study found semaglutide reduced the heart's biological age by two to four years and reduced organ biological age for the lungs, kidneys, brain, and pancreas by one to four years.
- ▪Eli Lilly's Surmount V clinical trial data on tirzepatide showed biological aging reduced by 0.7 to 1.1 years across different epigenetic clocks among adults over age 50 after 72 weeks.
GLP-1 cardiovascular benefits
- ▪Research presented at the European Respiratory Society Congress linked GLP-1 medications to reduced asthma attacks and chronic obstructive pulmonary disease flare-ups.
- ▪A study published in The Lancet showed semaglutide reduced heart attack, stroke, and cardiovascular death risk among people with cardiovascular disease and overweight or obesity regardless of baseline body weight.
GLP-1 kidney protection
- ▪Clinical research shows semaglutide slows kidney disease progression through mechanisms including blood sugar, blood pressure, and inflammation improvements.
- ▪The FLOW trial published in the New England Journal of Medicine demonstrated semaglutide reduced major kidney-related complications and cardiovascular death by 24% in patients with type 2 diabetes and chronic kidney disease.
GLP-1 liver protection
- ▪A clinical trial published in the New England Journal of Medicine showed 62.9% of metabolic dysfunction-associated steatohepatitis patients taking semaglutide achieved disease resolution without worsening liver fibrosis, compared with 34.3% taking placebo.
- ▪Semaglutide administration improved liver tissue findings, including reduced inflammation and liver scarring, among patients with metabolic dysfunction-associated steatohepatitis in a New England Journal of Medicine trial.
GLP-1 joint pain reduction
- ▪The STEP 9 clinical trial in the New England Journal of Medicine demonstrated semaglutide significantly reduced knee osteoarthritis pain and improved physical function among adults with obesity.
- ▪A JAMA Dermatology study found adding tirzepatide to existing psoriasis treatment improved skin clearance in adults with moderate to severe psoriasis and overweight or obesity.
GLP-1 psychiatric hospitalization reduction
- ▪Research published in Lancet Psychiatry found schizophrenia patients taking GLP-1 diabetes drugs had a 29% lower likelihood of emergency room visits for mental health crises compared to non-users.
- ▪A study in Lancet Psychiatry using U.S. health records showed people with schizophrenia taking GLP-1 drugs for diabetes were 24% less likely to be admitted to psychiatric hospitals.
- ▪A clinical trial starting in early 2027 by the Center for Addiction Science, Policy and Research and Allegheny County will evaluate weekly semaglutide injections in 1,200 participants with substance use disorders.
Story comments
Loading comments…